RHO.DU : Summary for ROCHE HLDG AG INH. SF 1 - Yahoo Finance

U.S. Markets closed

ROCHE HLDG AG INH. SF 1 (RHO.DU)


Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
Add to watchlist
231.33+0.05 (+0.02%)
At close: 8:27AM CET
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close231.28
Open231.33
Bid233.76 x
Ask233.98 x
Day's Range231.33 - 231.33
52 Week Range227.53 - 234.27
Volume0
Avg. Volume11
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Merck, Roche Gouge Bristol's I-O Share After Lung Cancer Approvals
    Investor's Business Daily3 days ago

    Merck, Roche Gouge Bristol's I-O Share After Lung Cancer Approvals

    Merck and Roche are swiping share from Bristol-Myers Squibb's I-O drugs after their FDA approvals in advanced lung cancer.

  • Reuters8 days ago

    Roche says Phase II trial supports twin treatment for kidney cancer

    Swiss pharmaceuticals company Roche said on Saturday that a combination of its immunotherapy drug Tecentriq and its blockbuster cancer drug Avastin had shown encouraging results in a Phase II trial in treating a type of kidney cancer. The study found that the combination had a "manageable safety profile" when used for locally advanced or metastatic renal cell carcinoma (mRCC). The tests showed promising effectiveness compared with the standard treatment for mRCC, sunitinib, which is sold by Pfizer under the brand name Sutent.

  • These Are The First Immune-System Cancer Drugs OK'd By FDA
    Investor's Business Daily9 days ago

    These Are The First Immune-System Cancer Drugs OK'd By FDA

    A handful of products define the new market for drugs that harness the immune system to fight cancer. Here's a list of the drugs and their FDA-approved uses.